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AggregateTDP-43 inclusions are an important histopathological feature in various neurodegenerative disorders, including
Amyotrophic Lateral Sclerosis and Fronto-Temporal Lobar Degeneration. However, the relation of these inclu-
sionswith the pathogenesis of the disease is still unclear. In fact, the inclusions could be toxic themselves, induce
loss of function by sequestering TDP-43 or a combination of both. Previously, we have developed a cellularmodel
of aggregation using the TDP-43 Q/N rich amino acid sequence 331–369 repeated 12 times (12xQ/N) and have
shown that these cellular inclusions are capable of sequestering the endogenous TDP-43 both in non-neuronal
and neuronal cells. We have tested this model in vivo in the Drosophila melanogaster eye. The eye structure
develops normally in the absence of dTDP-43, a fact previously seen in knock out ﬂy strains. We show here
that expression of EGFP 12xQ/N does not alter the structure of the eye. In contrast, TBPH overexpression is
neurotoxic and causes necrosis and loss of function of the eye. More important, the neurotoxicity of TBPH can
be abolished by its incorporation to the insoluble aggregates induced by EGFP 12xQ/N. This data indicates that
aggregation is not toxic per se and instead has a protective role, modulating the functional TBPH available in
the tissue. This is an important indication for the possible pathological mechanism in action on ALS patients.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The human hnRNP TDP-43 has shifted from a modest player in
obscure splicing mechanisms (Buratti and Baralle, 2001) to the main
protagonist in the pathogenesis of neurodegenerative diseases,
such as Amyotrophic Lateral Sclerosis and Fronto-Temporal Lobar
Degeneration. TDP-43 is mislocalized to the cytoplasm in the affected
neurons of ALS patients, forming inclusions that contain ubiquitinated,
hyperphosphorylated and cleaved TDP-43 (Neumann et al., 2006; Arai
et al., 2006). This observation was followed by the identiﬁcation in
2008 of mutations in the TARDBP gene in ALS patients (Sreedharan
et al., 2008; Kabashi et al., 2008). However, it is important to notice
that TARDBP gene mutations represent 1% of sALS cases and 4% of
fALS cases, but TDP-43 is found aggregated in the 97% of all ALS cases
(Ling et al., 2013). Thismeans that TDP-43 aggregates in patientsmostly43; TBPH/dTDP-43, TAR DNA-
, Amyotrophic Lateral Sclerosis;
69; UAS, upstream activating
ect.com).
should be considered joint ﬁrst
. This is an open access article underin the absence of TARDBP mutations, making the understanding of the
aggregation process more difﬁcult. TDP-43 inclusions are the main his-
topathological feature of the disease, but their relation with the patho-
genesis of ALS is still unclear. The possibilities that the inclusions could
be toxic themselves induce loss of function by sequestering TDP-43 and
hence depleting the nucleus of this essential factor or a combination of
both these possibilities has been considered.
It iswell known that lack of TDP-43 is deleterious for the cells and for
the organisms in general (Ayala et al., 2008; Feiguin et al., 2009; L.-S. Wu
et al., 2010). On the other hand, excessive production of TDP-43 is harm-
ful for the cells and thewhole organism, evenwhen there is no detectable
aggregation (Barmada et al., 2010; Hanson et al., 2010; Wegorzewska
et al., 2009). Not surprisingly, a very tight self-regulation mechanism is
in place to ensure the right level of TDP-43 in cells, whereby TDP-43 con-
trols itsmRNAproduction at post-transcriptional RNAprocessing level by
binding to its own transcript and triggering a series of events that lead to
degradation of the RNA (Ayala et al., 2011; Avendaño-Vázquez et al.,
2012; Bembich et al., 2013).
The mechanisms that trigger aggregation and how the aggregates
increase in size are unknown. Several attempts were done to mimic
the TDP-43 aggregation in cells. It was early observed that the TDP-43
C-terminal tail contains a Q/N rich region that is involved in protein–
protein interaction (D'Ambrogio et al., 2009). Moreover, it was shown
that expression of C-terminal fragments of TDP-43 is sufﬁcient to
generate cytoplasmic aggregates (Igaz et al., 2009). The importancethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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aggregation process was also conﬁrmed by Fuentealba et al. (Fuentealba
et al., 2010). Based on this information and with the aim of looking for
methodologies that could model the disease, we have developed a
cellular model of aggregation using a 30 amino acid TDP-43 C-terminal
peptide to promote TDP-43 aggregation (Budini et al., 2012a; Budini
et al., 2012b). The inclusion bodies formed are predominantly cytoplas-
mic, ubiquitinated and phosphorylated like the ones found in patients.
An animal model to extend these studies looking at in vivo phenotypes
was needed and, in the ﬁrst place, it was essential to test the aggregation
proﬁle in neurons and the effect it has on TDP-43 concentration in the
target tissues.
TDP-43 is a highly conserved protein, which has a very close ortholog
in Drosophila melanogaster, coded by the TBPH gene. As regards their
binding activity and their role in splicing, the human and Drosophila
proteinswere shown to be interchangeable (Ayala et al., 2005). Further-
more, the deletion of the TBPH gene results in a locomotion defective ﬂy
(D23 and D142 strains), whose climbing ability could be restored with
the expression in motor neurons of both Drosophila and human TDP-
43 (Feiguin et al., 2009). The D23 and D142 ﬂies do not present any ev-
ident externalmorphology alteration, and the eye structure is complete-
ly conserved (Feiguin et al., 2009). It follows that while TBPH plays a
fundamental structural and functional role in locomotion (i.e.: neuro-
muscular junction development and maintenance), it is not essential
for the development of a normal eye structure. This organ is then an
ideal testing ground to study the interplay between TBPH overexpres-
sion and aggregation.
The results described here analyze the effect of TBPH overexpression
in the eye, its toxic effects and their reduction by the formation of TBPH
aggregates. Our results show that aggregation is not toxic per se. Fur-
thermore, in the retinal tissue we demonstrated that the aggregates
have a protective role, as they capture and insolubilize the excess of
TBPH, blocking its toxic effect.Materials and methods
Transgenic ﬂies
Endogenous TBPH, its truncated form TBPHΔC (1–332) and human
Tau cDNA (4N2R isoform) were Flag tagged and cloned in pKS69.
EGFP-12xQ/N (12 repetitions of the TDP-43 331–369 sequence)
and EGFP constructs were cloned in the pUASTattB vector (Bischof
et al., 2007). All the constructs have been sequenced and subse-
quently used to create transgenic ﬂies by standard embryo injections
(Best Gene Inc.). While random insertions in yellow-white stain
have been chosen for TBPH, TBPHΔC and human Tau, a speciﬁc inser-
tion using strain 24486 was chosen for EGFP-12xQ/N and EGFP. All
transgenic ﬂies have been subsequently balanced on the required
chromosome.
W1118, Oregon-R and GMR-Gal4 were obtained from Bloomington
Drosophila Stock Center at Indiana University. Flies were fed on stan-
dard cornmeal (2.9%), sugar (4.2%), yeast (6.3%) ﬂy food, maintained
and crossed in a humidiﬁed incubator at 25 °C with a 12 hour–12 hour
light–dark cycle.Light microscopy of ﬂy eyes
Eye phenotypes of 1 day-old ﬂies were analyzedwith a stereomicro-
scope (Leica MZ75) and photographed with a camera (Leica DFC420C).
For the quantitative analysis of the induced eye phenotypes we de-
ﬁned arbitrarily 3 categories: (1) normal eye, (2) loss of pigmentation
and small regions of necrosis and (3) loss of pigmentation and massive
regions of necrosis. At least 50 1 day-old ﬂies were analyzed for each
genotype.Immunoblot
Drosophila heads were homogenized in lysis buffer (10 mM Tris–
HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 10% glycerol,
50 mMNaF, 5 mMDTT, 4 M urea, and protease inhibitors (Roche Diag-
nostic # 11836170001)). Proteins were separated by 8% SDS-PAGE,
transferred to nitrocellulose membranes (Whatman # NBA083C) and
probed with primary antibodies: rabbit anti-TBPH (1:3000, home-
made) and mouse anti-tubulin (1:4000, Calbiochem # CP06). The
membranes were incubated with the secondary antibodies: HRP-
labeled anti-mouse (1:1000, Thermo Scientiﬁc # 32430) or HRP-labeled
anti-rabbit (1:1000, Thermo Scientiﬁc # 32460). Finally, protein detec-
tionwas assessedwith Femto Super Signal substrate (Thermo Scientiﬁc
# 34095).Immunostaining
Immunostaining was performed according to standard protocols
(J. S. Wu and Luo, 2006). Brieﬂy, wandering third instar larvae were
dissected in phosphate buffer and ﬁxed in ice-cold 4% paraformalde-
hyde (Alfa Aesar # 30525-89-4) for 20min,washed in Phosphate Buffer
with 0.1% Tween 20 (PBT) and blocked with Normal Goat Serum (NGS,
Chemicon # S26-100 ML) 30 min at room temperature. The samples
were incubated with primary antibodies mouse anti-FlagM5 (1:200,
Sigma # F4042), rabbit anti-GFP (1:250, Life technologies # A11122)
and rat anti-ELAV (1:300, Hydridoma bank # 7E8A10) over night at
4 °C with agitation, and treated with ﬂuorescent conjugated secondary
antibodies Alexa 555 anti-mouse (1:500, Invitrogen # A21422), Alexa
488 anti-rabbit (1:500, Invitrogen # A11008) and Alexa 647 anti-rat
(1:500, Invitrogen # A21472) for 2 h at room temperature. All primary
and secondary antibodies were diluted in PBT-5% NGS. SlowFade Gold
Antifade reagent (Life technologies # S36936) was used as a mounting
medium. The samples were imaged under a confocal laser-scanning
microscope (LSM 510 META; Carl Zeiss, Inc.). Images were acquired
by using 63× oil immersion objective and 2× zoom. Image processing
was done with ImageJ software. All images were displayed as a single
section of 0.5 μm.Solubility test
24 adult ﬂy headswere dissected and homogenized in 192 ul of RIPA
buffer (50 mM Tris–HCl, pH 8, 150 mMNaCl, 2 mM EDTA, 1% Nonidet-
P40 (v/v), 0.1% SDS, 1% Na-deoxycholate and a cocktail of protease
inhibitors (Roche Diagnostic # 11836170001)). The samples were
incubated under agitation for 1 h at 4 °C and then centrifuged at
1000 g for 10 min at 4 °C. An aliquot was taken at this point as the
input, and after a further centrifugation step at 100,000 g for
30 min at 4 °C, the supernatant was collected as the soluble fraction.
The remaining pellet was re-extracted in 60 ul of urea buffer (9 M
urea, 50 mM Tris–HCl, pH 8, 1% CHAPS and a cocktail of protease in-
hibitors (Roche # 04693159001)) and spun down to remove any
precipitate, while the 9 M urea soluble material was collected as
the insoluble fraction. Proteins were separated by 8% SDS-PAGE.
The different samples were loaded in a proportion 1:1:1 for the
input, soluble and insoluble fractions. Proteins were electro-blotted
to a nitrocellulose membrane (Whatman # NBA083C) and probed
with the following primary antibodies: rabbit anti-TBPH (1:3000,
home-made), mouse anti-GFP (1:2000, Roche # 11814460001)
and mouse anti-tubulin (1:4000, Calbiochem # CP06). The mem-
branes were incubated with the secondary antibodies: HRP-labeled
anti-mouse (1:1000, Thermo Scientiﬁc # 32430) or HRP-labeled
anti-rabbit (1:1000, Thermo Scientiﬁc # 32460). Finally, protein
detection was assessed with Femto Super Signal substrate (Thermo
Scientiﬁc # 34095).
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1 day-old ﬂies were transferred without anesthesia to a 15 ml coni-
cal tube, tapped to the bottom of the tube, and their subsequent
climbing activity was quantiﬁed as number of ﬂies that reach the top
of the tube in 15 s. At least 100 ﬂies of each genotype were tested. In
each set of experiments 20 ﬂies were introduced in the cylinder and
tested three times. The number of top climbing ﬂies was converted
into % value, and the mean % value (±SEM) was calculated for at least
5 experiments.Phototaxis assay
Phototaxis assay was performed in a Y-maze with one arm exposed
to violet light (peakwavelength 400 nm) and the other arm completely
in the dark. Flies from each genotype were independently introduced
into the stem of the Y-maze, and had the choice between violet light
and the dark. After 30 s the number of ﬂies that moved towards the
illuminated chamber was determined. In each test 50 ﬂies were ana-
lyzed. At least 100 ﬂies of each genotype were tested. The number of
phototactic ﬂies was converted into % value, and the mean % value
(±SEM) was calculated.Statistics
One-way ANOVA followed by Bonferroni's multiple comparisonwas
used to compare measures among 4 groups. Unpaired t-test analysis
was used to compare measures between 2 groups. The signiﬁcance
between the variables was shown based on the p-value obtained (ns
indicates p N 0.05, * indicates p b 0.05, ** indicates p b 0.01, *** indicates
p b 0.001 and **** indicates p b 0.0001). Values are presented as amean
and error bars indicate standard error of the mean (SEM).Results and discussion
EGFP-12xQ/N expression forms insoluble aggregates in retinal cells with no
consequence for the eye structure
Our previously developed cellular model of TDP-43 aggregation
showed that repeated TDP-43 amino acid sequence 331–369 (12xQ/N)A
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Fig. 1. (a) Western blot of fractionated proteins obtained from GMR-Gal4;UAS-EGFP-12xQ/N a
insoluble fractions. The proteins were detected using an anti-GFP antibody. EGFP-12xQ/N is ma
served as loading control. (b) External eye phenotype of ﬂies GMR-Gal4;UAS-EGFP-12xQ/N anis capable of interacting with TDP-43 inducing its aggregation both in
non-neuronal and neuronal cells (Budini et al., 2012a).
To determinatewhether similar interactions occur in vivo, we created
transgenic D. melanogaster lines encoding either the Drosophila TDP-43
ortholog, TBPH, or the 12 repetitions of the 331–369 sequence of TDP-
43 tagged with EGFP (EGFP-12xQ/N), under the control of the upstream
activating sequence (UAS) (Brand and Perrimon, 1993).
After crossing the transgenic line EGFP-12xQ/Nwith the eye-speciﬁc
GMR-Gal4 driver, we analyzed biochemically the solubility of the
expressed protein and observed that EGFP-12xQ/N is mainly in the
insoluble fraction, while EGFP alone is a soluble protein (Fig. 1a).
Moreover, we found that neither the expression of the EGFP-12xQ/N,
nor the expression of EGFP alone affect the external structure of the
eye (Fig. 1b), meaning that EGFP-12xQ/N aggregates, per se, are not
neurotoxic.
EGFP-12xQ/N expression rescues TBPH-induced neurodegeneration
As reported for the human protein (Li et al., 2010; Miguel et al.,
2011), the overexpression of TBPH with the GMR-Gal4 driver induced
a remarkable degeneration of the external surface of the eye, with the
formation of necrotic patches, followed by the consistent loss of eye
pigmentation (compare Figs. 2a and b). Surprisingly, such a strong neu-
rodegeneration was completely reverted by the co-expression of TBPH
together with EGFP-12xQ/N (Fig. 2c). We assumed that this improve-
mentwas due to themodulation of the TBPH cellular levels by sequestra-
tion of the protein in the EGFP-12xQ/N aggregates.
Such recovery of the degenerated phenotype is 12xQ/N related and
cannot be due to a non-speciﬁc effect since the co-expression of EGFP,
without the 12xQ/N tail, and TBPH did not prevent the retinal degener-
ation induced by TBPH expression (Fig. 2d). A quantitative analysis of
the phenotypes was performed examining at least 50 ﬂies per genotype
(Fig. 2e).
The TBPH C-terminal amino acids are essential for the interaction with the
EGFP-12xQ/N aggregates
In previously published results (Budini et al., 2012a) we demonstrat-
ed that the C-terminal tail of human TDP-43 is the part of the protein
required for the protein–protein interaction. The expression of TBPH
lacking the C-terminal tail under GMR-Gal4 driver induced also a strongb 
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nd GMR-Gal4;UAS-EGFP adult ﬂy heads. Total proteins were fractionated into soluble and
inly an insoluble protein, whereas EGFP alone is found only in the soluble fraction. Tubulin
d GMR-Gal4;UAS-EGFP, the external eye phenotype of both ﬂies is completely normal.
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Fig. 2. External eye phenotype of ﬂies: (a) Oregon-R, (b) GMR-Gal4/UAS-TBPH, (c) GMR-Gal4/UAS-TBPH;UAS-EGFP-12xQ/N, (d) GMR-Gal4/UAS-TBPH;UAS-EGFP, (f) GMR-Gal4;UAS-
TBPHΔC, (g) GMR-Gal4;UAS-TBPHΔC/UAS-EGFP-12xQ/N, (h) GMR-Gal4;UAS-Tau, (i) GMR-Gal4;UAS-Tau/UAS-EGFP-12xQ/N. (e) Quantiﬁcation of eye defects for Oregon-R, GMR-
Gal4/UAS-TBPH, GMR-Gal4/UAS-TBPH;UAS-EGFP-12xQ/N, GMR-Gal4/UAS-TBPH;UAS-EGFP ﬂies. We deﬁned arbitrarily 3 categories: (1) normal eye, (2) loss of pigmentation and
small regions of necrosis and (3) loss of pigmentation and massive regions of necrosis. Expression of TBPH induces degeneration in Drosophila eye (b). The co-expression of EGFP-
12xQ/N rescues the eye degeneration (c), whereas the co-expression of EGFP alone does not change the phenotype induced by TBPH expression (d). On the other hand, expression of
TBPHΔC also induces degeneration inDrosophila eye (f). The co-expression of EGFP-12xQ/N does not rescue this degeneration (g). The expression of Tau also induces degeneration inDro-
sophila eye (h), and the co-expression of EGFP-12xQ/N does not rescue this degeneration (i).
77L. Cragnaz et al. / Neurobiology of Disease 71 (2014) 74–80phenotype in the eye that includes rough degeneration of the eye surface
andextensivedepigmentationof the retina (Fig. 2f). Although this pheno-
type was milder compared to the expression of the TBPH full-length
protein, we did not observe any modiﬁcation of the phenotype upon
co-expression of TBPHΔC and EGFP-12xQ/N (compare Figs. 2f and g).
This result suggests that the direct interaction between these proteins
is required to prevent TBPH-mediated neurodegeneration.
Moreover, we investigated if the effect seen with EGFP-12xQ/N was
speciﬁc for the neurodegeneration induced by TBPHoverexpression. For
this purpose, we focused on Tau protein, which is involved in other
proteinopathies. Tau expression in Drosophila eye caused degenerationof the retinal tissue, which could not be rescue by the co-expression of
EGFP-12xQ/N (compare Figs. 2h and i).
EGFP-12xQ/N expression promotes TBPH aggregation in retinal cells
Importantly, EGFP-12xQ/N expression does not suppress the TBPH-
induced eye phenotype simple through down-regulation of transgene
expression, as reveled by western blot analysis (Fig. 3). Co-expression
of TBPH and EGFP-12xQ/N or EGFP did not change the total TBPH
level, pointing to a different functionality of the protein, most probably
due to its physical status.
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Fig. 3. (a) Quantiﬁcation of TBPH level on total protein extracts prepared from adult ﬂy
heads GMR-Gal4/UAS-TBPH;UAS-EGFP-12xQ/N (1) and GMR-Gal4/UAS-TBPH;UAS-EGFP
(2). A representative western blot is shown. Tubulin was used as a loading control.
(b) Image J quantiﬁcation of TBPH was performed from three independent experiments.
ns indicates p N 0.05 (not signiﬁcant) calculated by unpaired t-test. Error bars indicate
SEM.
78 L. Cragnaz et al. / Neurobiology of Disease 71 (2014) 74–80In order to further explore the mechanism behind the recovery of
the TBPH-induced eye phenotype by EGFP-12xQ/N expression, we
looked for potential modiﬁcations in the intracellular pattern of TBPH
by performing a biochemical fractionation of the Drosophila adult head
proteins extracted from GMR-Gal4/UAS-TBPH;UAS-EGFP and GMR-
Gal4/UAS-TBPH;UAS-EGFP-12xQ/N expressing ﬂies. Fig. 4 shows a
clear shift in the TBPH solubility pattern when it is co-expressed
with EGFP-12xQ/N compared with EGFP control. In the case of GMR-
Gal4/UAS-TBPH;UAS-EGFP ﬂies, TBPH appears mainly in the soluble
fraction, whereas in GMR-Gal4/UAS-TBPH;UAS-EGFP-12xQ/N ﬂies, the
majority of the TBPH is present in the insoluble fraction.
EGFP-12xQ/N and TBPH co-localize in the Drosophila eye discs
The fact that the TBPH-induced degeneration was completely res-
cued when EGFP-12xQ/N was co-expressed with TBPH (Fig. 2c), taken
together with the solubility data reported above (Fig. 4), implied thatIN
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Fig. 4.Western blot of fractionated proteins obtained from GMR-Gal4/UAS-TBPH;UAS-
EGFP-12xQ/N and GMR-Gal4/UAS-TBPH;UAS-EGFP adult ﬂy heads. Total proteins were
separated into soluble and insoluble fractions. Proteins were detected with anti-TBPH an-
tibody (arrow and high molecular weight (HMW) species). Tubulin served as a loading
control. Co-expression of EGFP-12xQ/N and TBPH leads to formation of insoluble protein
aggregates. In contrast, TBPH remains mainly soluble when it is co-express with EGFP.TBPH may be sequestered in the EGFP-12xQ/N aggregates, allowing a
reduction in TBPH availability and avoiding the relative degeneration
induced by its high level. To test this hypothesis we analyzed the local-
ization of both proteins in the retinal cells. Immunohistochemistry of
the third instar larvae eye discs was performed in order to examine
the cellular distribution of the proteins, in GMR-Gal4/UAS-TBPH;UAS-
EGFP and GMR-Gal4/UAS-TBPH;UAS-EGFP-12xQ/N transgenic lines. In
the case of the larvae expressing TBPH and EGFP, both proteins were
homogeneously distributed (Fig. 5a), while TBPHwas found aggregated
and co-localizingwith the EGFP-12xQ/N aggregateswhen both proteins
were co-expressed (Fig. 5b).Moreover, we conﬁrmed that the observed
co-localization of TBPH and EGFP-12xQ/N in the aggregates was abro-
gated when the C-terminal tail of TBPH was not present (Fig. 5c).
It can be concluded that the neurotoxicity caused by increased
level of TBPH in vivo is modulated by its aggregation. In fact, the co-
expression of EGFP-12xQ/N in Drosophila eye is protective by titrating
the excess of the active TBPH.
This effect differs from theprotective role postulated for Lewy bodies
(present in Parkinson's disease and composed mainly by mutant α-
synuclein), hyperphosphorylated Tau aggregates (Alzheimer's disease)
and huntingtin inclusions that result from polyglutamine expansions
(Huntington's disease). In all these cases, it has been proposed that
the toxicity is a consequence of a mutation or abnormal modiﬁcation
of the protein, and that the aggregation is able to reduce this toxicity
(Arrasate et al., 2004; Cowan and Mudher, 2013; Tanaka et al., 2004).
However, in our case, the aggregates have a protective effect as just
remove the wild type TBPH in excess.
EGFP-12xQ/N expression restores eye functionality in TBPH expressing ﬂies
To determinate whether the suppression of TBPH toxicity by EGFP-
12xQ/N is correlated with eye functionality, phototaxis assay was per-
formed with 1 day-old ﬂies of the different genotypes (Fig. 6a). TBPH
overexpressing ﬂies were not attracted to the light source, meaning
that they were blind, consistent with the defective morphology of the
eye structure. In ﬂies co-expressing TBPH and EGFP-12xQ/N the vision
was restored to normal levels, as there was not signiﬁcant difference
compared to the wild type ﬂies, consistent with the recovery of the
eye morphology. Moreover, the visual deﬁcit was still present in ﬂies
co-expressing EGFP and TBPH.
Fig. 6b shows that the climbing ability of theﬂies of all the genotypes
analyzed was comparable to the wild type ﬂies, meaning that the nega-
tive phototaxis result is not due to a motor impairment.
Conclusions
We have shown here that the neurotoxicity caused by increased
level of TBPH in vivo can be modulated by its aggregation. The co-
expression of EGFP-12xQ/N, an inducer of TBPH aggregation, in
Drosophila eye is protective, because the excess TBPH becomes a
non-functional insoluble protein as part of the induced inclusions.
TDP-43 has a natural tendency to aggregate and in normal circum-
stances a small fraction of the protein is insoluble in the tissues. During
aging, the clearance of TDP-43 aggregates by, for example, the autoph-
agy pathway or by the proteasomes may become more difﬁcult. The
increasing capture of TDP-43 by growing cytoplasmic aggregates may
lower the amount of TDP-43 returning to the nucleus. This drop in levels
will be sensed by the self-regulation mechanism, and may in turn in-
crease the TDP-43 mRNA levels and hence the protein levels. This over-
expression of TDP-43 could be initiallymodulated by the aggregates that
capture the protein in excess, maintaining acceptable levels of active
protein in the cell. However, continued addition to the inclusions will
make them grow to a point in which they will capture so much protein
that the nuclear capacity to produce TDP-43 mRNA will be overcome.
This situation will lead to a lack of TDP-43, and its nuclear function
will be lost, leading to neuronal loss.
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Fig. 5. Confocal images of third instar larvae eye disc co-expressing TBPH and EGFP (a), TBPH and EGFP-12xQ/N (b), TBPHΔC and EGFP-12xQ/N (c). Samples were stained for ELAV, Flag-
TBPH, and EGFP. All the ﬁgures correspond to a single confocal section.
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Fig. 6.Phototaxis assay of 1-day-oldﬂies of different genotypes indicated as follows: (1)Oregon-R, (2)GMR-Gal4/UAS-TBPH, (3)GMR-Gal4/UAS-TBPH;UAS-EGFP-12xQ/N, (4) GMR-Gal4/
UAS-TBPH;UAS-EGFP. Flies expressing TBPH are not attracted to the light, whereas ﬂies co-expressing TBPH and EGFP-12xQ/N are attracted in the same proportion as wild type ﬂies. On
the contrary, the co-expression of TBPH and EGFP does not restore the vision. **** indicates p b 0.0001 andns indicates p N 0.05 (not signiﬁcant) calculated by one-wayANOVA followedby
Bonferroni'smultiple comparison. Error bars indicate SEM. (b) Climbing assay of 1-day-oldﬂies of different genotypes. The climbing ability of all the genotypeswas comparable to thewild
type. ns indicates p N 0.05 (not signiﬁcant) calculated by one-way ANOVA followed by Bonferroni's multiple comparison. Error bars indicate SEM.
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